Investing.com - Zentalis Pharma (NASDAQ: ZNTL) reported first quarter EPS of $0.14, $0.95 better than the analyst estimate of $-0.81. Revenue for the quarter came in at $40.56M versus the consensus estimate of $11.67M.
Zentalis Pharma's stock price closed at $11.72. It is up 1.91% in the last 3 months and down -44.88% in the last 12 months.
Zentalis Pharma saw 2 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Zentalis Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Zentalis Pharma's Financial Health score is "fair performance".
Check out Zentalis Pharma's recent earnings performance, and Zentalis Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar